Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava

Food and Chemical Toxicology

Volumn 49, Issue 11, 2011, Pages 2820-2829

  Behl, Mamta ^a   Nyska, Abraham ^b   Chhabra, Rajendra S ^a   Travlos, Gregory S ^a   Fomby, Laurene M ^c   Sparrow, Barney R ^c   Hejtmancik, Milton R ^c   Chan, Po C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b INTEGRATED LABORATORY SYSTEMS   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Gavage; Kava; Liver; Mice; Rats; Toxicity

Indexed keywords

BILE SALT; CORN OIL; GAMMA GLUTAMYLTRANSFERASE; KAVA;

ABNORMAL RESPIRATORY SOUND; ANIMAL EXPERIMENT; ARTICLE; ATAXIA; CHOLESTASIS; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY LIVER; FEMALE; HEPATOBLASTOMA; LETHARGY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER DISEASE; LIVER HYPERTROPHY; LIVER TOXICITY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; RAT; SURVIVAL RATE; TOXICITY TESTING;

ANIMALS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEMALE; KAVA; LIVER; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, INBRED F344; SEX CHARACTERISTICS;

MUS; PIPER METHYSTICUM; RATTUS; ZEA MAYS;

EID: 80052866052     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.07.067     Document Type: Article

References (93)

1. ABC News (1998). The Kava Craze: The Herb that May Relieve Stress and Anxiety. More Information on Kava. 20/20 Airdate, June 22, 1998. http://www.herbsnmore.com/2020rpt.html.
2. Allen D.G., Pearse G., Haseman J.K., Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 2004, 32:393-401.
3. Anke J., Ramzan I. Kava hepatotoxicity: are we any closer to the truth?. Planta Med. 2004, 70:193-196.
4. Bailer A.J., Portier C.J. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 1988, 44:417-431.
5. Basch E., Ulbricht C., Hammerness P., Tsouronis C., Sollars D., Rogers A., Basch S., Bent S., Boon H., Ernst E. Kava monograph: a clinical decision support tool. J. Herb Pharmacother. 2002, 2:65-91.
6. Bilia A.R., Gallon S., Vincieri F.F. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 2002, 70:2581-2597.
7. Boon H.S., Wong A.H. Kava: a test case for Canada's new approach to natural health products. Can. Med. Assoc. J. 2003, 169:1163-1164.
8. Brauer R.B., Stangl M., Stewart J.R., Pfab R., Becker K. Acute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum). J. Clin. Psychiatry 2003, 64:216-218.
9. Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005, 60:24-25.
10. Bucher J.R., Haseman J.K., Herbert R.A., Hejtmancik M., Ryan M.J. Toxicity and carcinogenicity studies of oxazepam in the Fischer 344 rat. Toxicol. Sci. 1998, 42:1-12.
11. Bujanda L., Palacios A., Silvariño R., Sánchez A., Muñoz C. Kava-induced acute icteric hepatitis. Gastroenterol. Hepatol. 2002, 25:434-435. [in Spanish].
12. Campo J.V., McNabb J., Perel J.M., Mazariegos G.V., Hasegawa S.L., Reyes J. Kava-induced fulminant hepatic failure. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:631-632.
13. Clayton N.P., Yoshizawa K., Kissling G.E., Burka L.T., Chan P.C., Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with Kava extract. Exp. Toxicol. Pathol. 2007, 58:223-236.
14. Clough A.R., Bailie R.S., Currie B. Liver function test abnormalities in users of aqueous kava extracts. J. Toxicol. Clin. Toxicol. 2003, 41:821-829.
15. Cox D.R. Regression models and life-tables. J. R. Stat. Soc. 1972, B34:187-220.
16. De Smet P.A. Safety concerns about kava not unique. Lancet 2002, 360:1336.
17. Denham A., McIntyre M., Whitehouse J. Kava - the unfolding story: report on a work-in-progress. J. Altern. Complement. Med. 2002, 8:237-263.
18. Dentali S.J. Herb Safety Review. Kava. Piper methysitucm Forster f. (Piperaceae) 1997, Herb Research Foundation, Boulder, CO, p. 29.
19. Dunn O.J. Multiple comparisons using rank sums. Technometrics 1964, 6:241-252.
20. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50:1096-1121.
21. Ernst E. Recall of the herbal anxiolytic Kava. Underestimation of its value or overestimation of its risks?. MMW Fortschr. Med. 2002, 144:40. [in German].
22. Ernst E. Safety concerns about Kava. Lancet 2002, 359:1865.
23. Ernst E. Herbal remedies for anxiety-a systematic review of controlled clinical trials. Phytomedicine 2006, 13:205-208.
24. Escher M., Desmeules J., Giostra E., Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001, 322:139.
25. Food and Drug Administration (FDA) (2001). Letter to health care professionals about FDA seeking information on liver injury and Kava products. <> Accessed on December 2006. http://www.cfsan.fda.gov/~dms/ds-ltr27.html.
26. Food and Drug Administration (FDA) (2002). Kava concerns. Botanical Council raises safety concerns. AWHONN Lifelines 6, 13-15.
27. Fong H.H. Integration of herbal medicine into modern medical practices: issues and prospects. Integr. Cancer Ther. 2002, 1:287-293.
28. Fu P.P., Xia Q., Guo L., Yu H., Chan P.C. Toxicity of Kava Kava. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2008, 26:89-112.
29. Fu S., Korkmaz E., Braet F., Ngo Q., Ramzan I. Influence of Kavain on hepatic ultrastructure. World J. Gastroenterol. 2008, 14:541-546.
30. Gardiner P., Graham R., Legedza A.T., Ahn A.C., Eisenberg D.M., Phillips R.S. Factors associated with herbal therapy use by adults in the United States. Altern. Ther. Health Med. 2007, 13:22-29.
31. Gow P.J., Connelly N.J., Hill R.L., Crowley P., Angus P.W. Fatal fulminant hepatic failure induced by a natural therapy containing Kava. Med. J. Aust. 2003, 178:442-443.
32. Gruenwald J., Skrabal J. Kava ban highly questionable: A brief summary of the main scientific findings presented in the " in depth investigation on EU member states market restrictions on kava products" Semin. Integrative Med. 2003, 1:199-210.
33. Guo L., Li Q., Xia Q., Dial S., Chan P.C., Fu P. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with Kava extract. Food Chem. Toxicol. 2009, 47:433-442.
34. Guo L., Shi Q., Dial S., Xia Q., Mei N., Li Q.Z., Chan P.C., Fu P. Gene expression profiling in male B6C3F1 mouse livers exposed to Kava identifies-changes in drug metabolizing genes and potential mechanisms linked to Kava toxicity. Food Chem. Toxicol. 2010, 48:686-696.
35. Hall R.L. Clinical pathology of laboratory animals. Animal Models in Toxicology 2007, 787-830. second ed. S.C. Gad (Ed.).
36. Hapke H.J., Sterner W., Heisler E., Brauer H. Toxicological studies with Kavaform. Farmaco. Ed. Prat. 1971, 26:692-720.
37. Hardisty J.G., Boorman G.A. National Toxicology Program pathology quality assurrance procedures. Managing Conduct and Data Quality of Toxicologic Studies 1986, 263-269. Princeton Publishing Company, Princeton. C. Whitmire, C.L. Davis, D.W. Bristol (Eds.).
38. Haseman J.K., Young E., Eustis S.L., Hailey J.R. Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicol. Pathol. 1997, 25:256-263.
39. Hefner D. FDA studying claims kava may be harmful. J. Natl. Med. Assoc. 2002, 94:285.
40. Hu Z., Yang X., Ho P.C., Chan S.Y., Heng P.W., Chan E., Duan W., Koh H.L., Zhou S. Herb-drug interactions: a literature review. Drugs 2005, 65:1239-1282.
41. Humberston C.L., Akhtar J., Krenzelok E.P. Acute hepatitis induced by Kava Kava. J. Toxicol. Clin. Toxicol. 2003, 41:109-113.
42. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5:6-13.
43. Jamieson D.D., Duffield P.H. The antinociceptive actions of kava components in mice. Clin. Exp. Pharmacol. Physiol. 1990, 17:495-507.
44. Jamieson D.D., Duffield P.H. Positive interaction of ethanol and kava resin in mice. Clin. Exp. Pharmacol. Physiol. 1990, 17:509-514.
45. Jhoo J.W., Ang C.Y., Heinze T.M., Deck J., Schnackenberg L.K., Beger R.D., Dragull K., Tang C.S. Identification of C-glycoside flavonoids as potential mutagenic compounds in Kava. J. Food Sci. 2007, 72:C120-C125.
46. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53:457-481.
47. Kopp, B. (2003). Relevant hepatotoxic effects of kava still need to be proven: A statement of the Society for Medicinal Plant Research. http://www.ga-online.org/files/misc/kava%20statement.pdf.
48. Kraft M., Spahn T.W., Menzel J., Senninger N., Dietl K.H., Herbst H., Domschke W., Lerch M.M. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch. Med. Wochenschr. 2001, 126:970-972. [in German].
49. Lebot V., Merlin M., Lindstrom L. Kava: The Pacific Drug 1992, Yale University Press, New Haven, CT, p. 225.
50. Lim S.T., Dragull K., Tang C.S., Bittenbender H.C., Efird J.T., Nerurkar P.V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci. 2007, 97:214-221.
51. Mathews J.M., Etheridge A.S., Black S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 2002, 30:1153-1157.
52. Mathews J.M., Etheridge A.S., Valentine J.L., Black S.R., Coleman D.P., Patel P., So J., Burka L.T. Pharmacokinetics and disposition of the Kavalactone Kavain: interaction with Kava extract and Kavalactones in vivo and in vitro. Drug Metab. Dispos. 2005, 33:1555-1563.
53. Mills E., Singh R., Ross C., Ernst E., Ray J.G. Sale of kava extract in some health food stores. Can. Med. Assoc. J. 2003, 169:1158-1159.
54. Mirasol F. Botanicals industry posts strong growth in US. Chem. Market Rep. 1998, 4(September):12-13.
55. National Research Council. (1996). Guide for the Care and Use of Laboratory Animals. Washington, DC, National Academies Press.
56. National Toxicology Program (NTP) (1993). Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies). Technical Report Series No. 443. NIH Publication No. 93-3359. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
57. National Toxicology Program (NTP). (2011). Toxicology and Carcinogenesis Studies of Kava Kava Extract (CAS No. 9000-38-8) in F344/N Rats and B6C3F1 Mice (Gavage Studies), draft report. National Toxicology Program, Research Triangle Park, NC.
58. Norton S.A., Ruze P. Kava dermopathy. J. Am. Acad. Dermatol. 1994, 31:89-97.
59. Nguyen H.T. Transport proteins. The Clinical Chemistry of Laboratory Animals 1999, 309-335. Taylor and Francis, Boca Raton, LA. second ed. W.F. Loeb, F.W. Quimby (Eds.).
60. Parkman C.A. Another FDA warning: Kava supplements. Case Manager 2002, 13:26-28.
61. Piegorsch W.W., Bailer A.J. Statistics for Environmental Biology and Toxicology, Section 6.3.2 1997, Chapman and Hall, London.
62. Pittler M.H., Ernst E. Efficacy of Kava extract for treating anxiety: systematic review and meta-analysis. J. Clin. Psychopharmacol. 2000, 20:84-89.
63. Pittler M.H., Ernst E. Kava extract for treating anxiety. Cochrane Database Syst. Rev. 2002, (2):CD003383.
64. Pittler M.H., Ernst E. Kava extract for treating anxiety. Cochrane Database Syst. Rev. 2003, (1):CD003383.
65. Poolsup N., Li Wan Po A., Knight T.L. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 2000, 25:197-220.
66. Portier C.J., Bailer A.J. Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam. Appl. Toxicol. 1989, 12:731-737.
67. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 2003, 31:533-539.
68. Robinson V., Bergfeld W.F., Belsito D.V., Klaassen C.D., Marks J.G., Shank R.C., Slaga T.J., Snyder P.W., Andersen F.A. Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract, cosmetic ingredient review expert panel. Int. J. Toxicol. 2009, 28:175S-188S.
69. Russmann S., Lauterburg B.H., Helbling A. Kava hepatotoxicity. Ann. Intern. Med. 2001, 135:68-69.
70. Russmann S., Barguil Y., Cabalion P., Kritsanida M., Duhet D., Lauterburg B.H. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. 2003, 15:1033-1036.
71. Schulze J., Raasch W., Siegers C.P. Toxicity of Kava pyrones, drug safety and precautions - a case study. Phytomedicine 2003, 10:68-73.
72. Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 1977, 33:386-389.
73. Shulgin A.T. The narcotic pepper-the chemistry and pharmacology of Piper methysticum and related species. Bull. Narc. 1973, 25:59-74.
74. Singh Y.N. Kava: an overview. J. Ethnopharmacol. 1992, 37:13-45.
75. Singh Y.N. Potential for interaction of kava and St. John's wort with drugs. J. Ethnopharmacol. 2005, 100:108-113.
76. Singh Y.N., Devkota A.K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 2003, 69:496-499.
77. Stafford, N. (2001). Germany may ban Kava Kava herbal supplement. Reuter's News Service, November 19, 2001, Germany.
78. Stickel F., Baumüller H.M., Seitz K., Vasilakis D., Seitz G., Seitz H.K., Schuppan D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. 2003, 39:62-67.
79. Sulakhe S.J., Tran T., Pulga V.B. Modulation of gamma-glutamyltranspeptidase activity in rat liver membranes by thyroid hormones. Int. J. Biochem. 1990, 22:997-1004.
80. Symmetry (1998). Tranquility. http://www.go-symmetry.com/catalog/tranquility.htm.
81. Tarone R.E. Tests for trend in life table analysis. Biometrika 1975, 62:679-682.
82. Teschke R., Gaus W., Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003, 10:440-446.
83. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20:1182-1193.
84. Thomsen M., Vitetta L., Schmidt M., Sali A. Fatal fulminant hepatic failure induced by a natural therapy containing Kava. Med. J. Aust. 2004, 180:198-199.
85. Unger M., Holzgrabe U., Jacobsen W., Cummins C., Benet L.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 2002, 68:1055-1058.
86. Wagner J.D., Greaves K.A., Schwenke D.C., Bauer J.E. Lipids and lipoproteins. The Clinical Chemistry of Laboratory Animals 1999, 181-228. Taylor and Francis, Boca Raton, LA. second ed. W.F. Loeb, F.W. Quimby (Eds.).
87. Wanwimolruk S., Bhawan S., Coville P.F., Chalcroft S.C. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur. J. Clin. Pharmacol. 1998, 54:431-435.
88. Whittaker P., Clarke J.J., San R.H., Betz J.M., Seifried H.E., de Jager L.S., Dunkel V.C. Evaluation of commercial Kava extracts and Kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food Chem. Toxicol. 2008, 46:168-174.
89. Whitton P.A., Lau A., Salisbury A., Whitehouse J., Evans C.S. Kava lactones and the kava-kava controversy. Phytochemistry 2003, 64:673-679.
90. Williams D.A. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 1986, 42:183-186.
91. Williams D.A. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971, 27:103-117.
92. Zou L., Harkey M.R., Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002, 71:1579-1589.
93. Zou L., Henderson G.L., Harkey M.R., Sakai Y., Li A. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004, 11:285-294.